摘要
以吸入激素(inhaled corticosteroid,ICS)为主联合长效β2激动剂等治疗可以使多数哮喘患者得到良好的临床控制。但目前的治疗方法仍不是最理想的疗法。新的治疗药物仍在不断地研发之中,包括新型的ICS、超长效的β2激动剂以及针对哮喘炎症细胞因子的"靶向"治疗药物等。今后这些药物的上市有可能进一步的改善哮喘的治疗。
The most primary of inhaled corticosteroid combined with long-acting β2-agomists can control the majority of asthma patients in clinical. But the present treatiment was not the ideal researches on new drugs. New drugs were kept reseanhing, such as new inhaled cortieosteroid, super long-acting [32-agonists and targeted therapy for inflammatory cytokines of asthma, etc. These medicine will improve the treatment of asthma after came into market in the future.
出处
《中华肺部疾病杂志（电子版）》
CAS
2010年第2期1-3,共3页
Chinese Journal of Lung Diseases(Electronic Edition)
关键词
支气管哮喘
药物
治疗
进展
Bronchial asthma
Drugs
Treatment
Progress
